Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan + amlodipine + hydrochlorothiazide triple therapy versus olmesartan + amlodipine dual therapy in hypertension
NL-OMON35387Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olmesartan, amlodipine and hydrochlorothiazide in essential hypertension (9 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Aug 2009; status: active, not recruiting.
02
Drugs
olmesartanamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NL-OMON35387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35387.